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The purpose of this study was to evaluate the efficacy, assesed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination
with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC). In all, 84 patients with recurrent or metastatic CRC with
measurable disease were included. Treatment consisted of oxaliplatin 85mgm
2 in 120-min intravenous (i.v.) infusion on days 1 and
15; i.v. l,leucovorin (l,LV) 250mgm
2 given in 2h on day 1, followed by oral UFT 390mgm
2 on days 1–14, and oral l,LV 7.5mg/
12h on days 2–14. Cycles were repeated every 28 days. A total of 492 cycles of chemotherapy were delivered with a median of six
per patient (range 1–12). There was one complete response (1%) and 28 partial responses (34%) for an overall response rate of
35% (95% confidence interval (CI): 24–46%). A total of 36 patients (44%) had stable disease, whereas 17 (21%) had a progression.
The median time to progression was 7.3 months and the median overall survival was 16.8 months. A prescheduled preliminary
analysis was performed after inclusion of 16 patients who detected a high gastrointestinal toxicity, which led to a reduction of the UFT
dose to 300mgm
2. With this new dosage, grade 3–4 diarrhoea and grade 3–4 nausea/vomiting dropped to 21 and 14% of
patients, respectively. Other grade 3–4 toxicities were stomatitis in one (1%), anaemia in three (5%), neutropenia in two (3%),
thrombocytopenia in one(1%), fatigue in six (9%), peripheral sensory neuropathy in nine (14%) and laryngopharyngeal dysesthesia in
two patients (2%). The combination of oxaliplatin and UFT–l,LV is an active, easy-to-administer regimen with moderate toxicity.
Hence, this regimen is worthy of further investigation.
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Although 5-fluorouracil (5FU) was developed approximately 50
years ago, it is still an essential part of advanced colorectal cancer
(CRC) treatment. It is currently accepted that 5FU continuous
infusion and biochemical modulation with leucovorin (LV)
increase response rates and time to progression compared to
schemas with bolus administration (Advanced Colorectal Meta-
Analysis Project, 1992; Meta-Analysis Group in Cancer, 1998a).
They also have a more favourable toxicity profile (Meta-Analysis
Group in Cancer, 1998b).
Over the last 10 years, significant activity has been observed
with other cytotoxics, such as irinotecan (CPT-11) and oxaliplatin,
in monotherapy treatment of this tumour type. The addition of
oxaliplatin or CPT-11 to 5FU–LV in randomised Phase III trials
has shown high antitumoral activity in patients with advanced
CRC (de Gramont et al, 2000; Douillard et al, 2000; Giacchetti et al,
2000; Saltz et al, 2000).
Although combined therapy has been an important develop-
ment in the treatment of advanced CRC, these schemes do have
some disadvantages. Firstly, their increased toxicity, particularly
when CPT-11 is combined with bolus 5FU–LV (Ledermann et al,
2001; Rothenberg et al, 2001). Secondly, continuous-infusion-
based regimens require the use of implantable access devices and
portable infusion pumps. In addition to the potential risk of
catheter-related complications, this type of regimen can restrict
patient activity, which can have a negative effect on their quality of
life. For this reason, oral chemotherapy may represent a
convenient and more acceptable treatment modality. Besides,
some studies indicate that patients prefer oral rather than
intravenous (i.v.) therapy, provided that efficacy remains the
same (Liu et al, 1997; Borner et al, 2002).
UFT is an oral combination of uracil and tegafur in a molar ratio
of 4:1. Tegafur is a prodrug that is metabolised into 5FU by
hepatic microsomal cytochrome P450 enzymes or by ubiquitous
cytosolic enzymes. Uracil inhibits the catabolism of 5FU by
competitive inhibition of the enzyme dihydropyrimidine-dehy-
drogenase, which maintains active drug levels for a prolonged
period and thus simulates a continuous infusion of 5FU. The
plasma half-life is of 5–12h (Fujii et al, 1979; Eng et al, 2001). In a
pharmacokinetic study, UFT 370mgm
2 given orally on a 28-day
schedule resulted in blood concentrations comparable to those
following a continuous i.v. infusion of 5FU 250mgm
2 (Ho et al,
Received 9 June 2004; revised 19 August 2004; accepted 19 August
2004; published online 26 October 2004
*Correspondence: Dr J Feliu; E-mail: jfeliu.hulp@salud.madrid.org
British Journal of Cancer (2004) 91, 1758–1762
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l1998). Two Phase III studies have been conducted to compare the
efficacy and toxicity of modulation of UFT and LV with 5FU–LV
(Carmichael et al, 2002; Douillard et al, 2002). Response rate and
overall survival were similar, although a slight disadvantage in
time to progression was observed for UFT–LV in one of the
studies (3.8 vs 3.5 months; Po0.05) (Douillard et al, 2002).
However, if we take these studies as a whole, it is acceptable to say
that they are equivalent in efficacy and that UFT–LV has a more
favourable toxicity profile, with less neutropenia, diarrhoea,
nausea/vomiting and mucositis (Mayer, 2001).
Some years ago, we developed a therapeutic scheme to modulate
UFT with LV. It consisted of the infusion of a high dose of
LV, followed by the oral administration of both UFT and LV for
14 days.
A Phase I trial determined that the maximum-tolerated dose
of UFT when modulated in this way was 390mgm
2day
1
(Gonza ´lez-Baro ´n et al, 1993). This regimen obtained a 39%
response rate in patients with advanced colon cancer, both
adults (Gonza ´lez-Baro ´n et al, 1995) and elderly patients (Feliu
et al, 1997).
Oxaliplatin is a third-generation platinum compound that has
synergistic antitumoral activity with 5FU (Raymond et al, 1997).
This synergistic activity is also observed when oxaliplatin is
combined with UFT–LV (Louvet et al, 2000).
Therefore, in the light of the above, it is to be expected that the
combination of oxaliplatin–UFT–LV will be at least as effective as
the combination of oxaliplatin–5FU–LV, although the former
could offer greater comfort for patients and a lower toxicity.
The purpose of this multicentre Phase II study is to assess the
efficacy (in terms of response rate) and safety of the oxaliplatin–
UFT–LV combination as first-line treatment in patients with
advanced CRC.
PATIENTS AND METHODS
Patient population
A total of 84 patients with recurrent or metastatic CRC were
included from April 1999 to January 2000. They all had at least one
lesion histologically or cytologically confirmed adenocarcinoma.
Patients who had received prior adjuvant 5FU-based chemother-
apy were eligible if they had remained free of disease for at least 6
months after completion of the adjuvant therapy. Patients with
operable metastatic disease were excluded from the study. Other
inclusion criteria were: (1) a performance status p2, according to
Eastern Cooperative Oncology Group (ECOG) scale. (2) Life
expectancy of at least 3 months. (3) Adequate bone marrow
function, that is, a granulocyte count X210
9l
1 and platelets
410010
9l
1. (4) Adequate hepatic function, that is, serum
bilirubin o1.25 times the upper normal limit, glutamic oxaloacetic
transaminase values (SGOT) and glutamic pyruvic transaminases
(SGPT) o 2.5 times the upper normal limit in the absence of
hepatic metastases or o5 times the upper normal limit in the
presence of metastasis. (5) Adequate renal function, that is, a
creatinine value p1.25 times the upper normal limit.
Patients with any prior chemotherapy for advanced disease,
brain or meningeal metastases, or a history of any other
malignancy were excluded, except in cases of basal cell carcinoma
or in situ cervical carcinoma adequately treated. Patients provided
written informed consent according to directives of local ethical
committees.
All patients had measurable disease, as defined by the presence
of at least one bidimensionally measurable lesion by computed
tomography scan. Pleural effusion, ascites, osteoblastic lesions or
previously irradiated lesions were not accepted as measurable
disease. Patients who had received radiotherapy were eligible if
there was at least one measurable lesion outside the radiation field.
Treatment plan
The study regimen consisted of oxaliplatin 85mgm
2 in 120-min
i.v. infusion in 250ml of dextrose 5% on days 1 and 15; i.v. l,LV
250mgm
2 given over 2h on day 1, followed by oral UFT
390mgm
2 on days 1–14; and oral l,LV 7.5mg12h
1 on days
2–14, followed by 2 weeks of rest. An entire course lasted 4 weeks.
Pills were taken before meals to favour absorption (for instance, at
0800 and 2000). For practical reasons, UFT doses were rounded up
or down to the nearest dose that could be administered with
100mg capsules of the drug. Routine antiemetic prophylaxis with a
5-hydroxytryptamine-3-receptor antagonist was used. Courses
were repeated every 28 days with a minimum of three per patient,
unless progressive disease was detected. Responding patients
continued therapy until progression or the appearance of
unacceptable toxicity.
Patients were assessed for toxicity before each course and
graded according to WHO scales (WHO, 1979). Complete blood
counts were obtained on days 1 and 14 of each cycle, before each
administration of oxaliplatin. Therapy was delayed for 1 week if
the neutrophil count was o1.510
9l
1 or the platelet count was
o10010
9l
1 or for significant persisting nonhaematologic
toxicity. Therapy was completely discontinued if toxicity persisted
after a 2-week delay. In case of grade 3 or 4 haematologic toxicity
or any other severe (Xgrade 3) organ toxicity, the dose of all drugs
was decreased by 25% in the subsequent cycles. The oxaliplatin
dose was reduced by 25% for subsequent cycles in case of
persistent (X14 days) or temporary (7–14 days) painful
paresthesia or functional impairment. In case of persistent painful
paresthesia or functional impairment, or if a patient experienced
any other severe neurotoxicity despite a 25% dose attenuation,
oxaliplatin was omitted in subsequent cycles. In case of the
occurrence of a laryngeal spasm syndrome, the duration of the
oxaliplatin infusion was increased from 2 to 6h. In case of
persistent problems, oxaliplatin was omitted.
Pretreatment and follow-up studies
Patients had a full clinical history, physical examination,
performance status assessment, haematological and biochemical
profiles (including CEA level), a chest X-ray and a computed
tomography scan of the chest and abdomen at baseline. Additional
imaging investigations were performed if clinically indicated. A
computed tomography scan was repeated every three courses to
assess objective response. At the end of chemotherapy, all clinical,
laboratory and imaging studies were repeated and patients
underwent follow-up examination every 2 or 3 months until death.
Toxicity and response criteria
Toxicity for each course was recorded and graded according to
WHO scales (WHO, 1979). For toxicity analysis, the worst data for
each patient across all courses were used. Response was evaluated
using WHO guidelines (WHO, 1979). A complete response
required the total disappearance of all tumours initially observed
in two observations not less than 4 weeks apart, with no evidence
of new areas of malignant disease. A partial response was defined
as a reduction of at least 50% in the sum of the products of the
longest perpendicular diameter of all clearly measurable tumour
masses, in two observations not less than 4 weeks apart, with no
increase in the size of any lesion and no evidence of new lesions.
Stable disease was defined as a decrease in total tumour size of less
than 50% or a less than 25% increase in any measurable lesion.
Progression was defined as a 25% increase in the size of any lesion,
the appearance of new areas of malignant disease or performance
status deterioration by more than one level. Time to tumour
progression was estimated by the product-limit estimation from
the date of the first course to the first evidence of disease
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lprogression. Radiological responses were not evaluated by an
Independent Review Committee (IRC). Survival was calculated by
the same method from the date of the first course until the date of
death or last known follow-up.
Statistical analysis
The primary end point was response rate and the secondary
objectives were survival and time to progression. Dose intensity
was calculated by dividing the total mgm
2 of drug given by the
number of weeks elapsed from the beginning of therapy to the end
of the last cycle.
The sample size was designed to reject a response rate of less
than 20%. A total of 19 patients were initially included using the
Fleming method (Fleming, 1982). Alternatively, a planned sample
size of 80 evaluable patients was chosen to better estimate efficacy;
20% of the maximum width of the 95% confidence interval (CI) for
an expected 35% overall response rate. The Wilcoxon’s rank-sum
method was used to compare quantitative variables, the Fisher’s
exact test for percentages and the Kaplan–Meier method for
survival and the duration of response. Progression-free survival
was measured from the start of chemotherapy to the date of
progressive disease or death without progression.
RESULTS
Patient characteristics
A total of 84 patients with recurrent or metastatic CRC were
included on the study. The characteristics of these patients are
shown in Table 1. The median age of the series was 63 years (range
40–77). In total, 47 patients were male (56%) and 37 were female
(44%). There were 41 patients (49%) with an ECOG performance
status of 0, 37 (44%) with 1 and 6 (7%) with 2. In 52 patients
(62%), the primary tumour was located in the colon and in 32
(38%) in the rectum. A total of 22 patients (26%) had previously
received chemotherapy as adjuvant therapy and other eight (10%)
had received chemotherapy and radiotherapy. The liver was the
predominant metastatic site (74%), and the median number of
involved sites was two per patient.
Treatment summary
A total of 492 cycles of chemotherapy were delivered with a median
of six cycles per patient (range 1–12). Eight patients (10%)
received less than three cycles of chemotherapy: four (5%) due to a
progression, two (2%) due to the patient’s refusal and a further two
(2%) because they moved to another city and were lost to follow-
up. With the exception of the last two patients, for whom no data
are available, the remaining 82 patients were evaluated for efficacy
and toxicity. The first 16 patients received UFT 390mgm
2day
1
but, because of the high toxicity associated with this dose, the
subsequent 66 patients received 300mgm
2day
1.
The median dose intensity of UFT was 1020mgm
2week
1
in the first group (83% of the scheduled dose) and
934mgm
2week
1 in the second group (89% of the scheduled
dose). The median dose intensity of oxaliplatin was
38.2mgm
2week
1, which corresponded to 90%. A total of 69
patients (82%) received 90% or more of the scheduled dose.
Response and survival
Response data are listed in Table 2. One patient (1%) obtained a
complete response and 28 (34%) had a partial response, with an
overall response rate of 35% (95% CI: 24–46%). A total of 36
patients (44%) had stable disease and 17 (21%) had a progression.
The median follow-up for all patients was 14 months. The median
duration of response was 7.8 months. The median time to
progression was 7.3 months, and the median overall survival
16.8 months. The 1-year actuarial survival rate was 71%.
Toxicity
The first 16 patients received UFT 390mgm
2day
1. Important
gastrointestinal toxicity was observed with grade 3–4 diarrhoea in
nine patients (56%) and grade 3–4 nausea/vomiting in three
(19%). One patient developed grade 3 neutropenia (6%) (Table 3).
As a result, the UFT dose was reduced to 300mgm
2 in
subsequent patients. This reduced dose was administered to 66
patients and the incidence of grade 3–4 diarrhoea and nausea/
vomiting dropped to 21 and 14% of patients, respectively. This
toxicity appeared preferentially in the first two cycles. Other grade
3–4 toxicities were stomatitis in one patient (1%), anaemia in
three (5%), neutropenia in two (3%), thrombocytopenia in one
(1%) and fatigue in six (19%). Oxaliplatin-associated peripheral
sensory neuropathy was observed in 73% of patients, with grade 3
neurotoxicity occurring in nine (14%) patients. Grade 3–4
laryngopharyngeal dysesthesia was observed in two patients
(2%), and could be prevented in the following treatment cycles
by prolonging the duration of oxaliplatin infusion.
Table 1 Patient characteristics
Characteristic No. (%)
Age (years) (mean and range) 63 (40–77)
Sex
Male 47 (56%)
Female 37 (44%)
ECOG performance status
0 41 (49%)
1 37 (44%)
2 6 (7%)
Primary site
Colon 52 (62%)
Rectum 32 (38%)
Metastasis sites
Liver 62 (74%)
Lung 25 (30%)
Local abdominal mass 16 (19%)
Others 19 (23%)
No. of metastatic sites
1 47 (56%)
2 32 (38%)
X3 5 (6%)
Adjuvant chemotherapy
Yes 30 (36%)
No 54 (64%)
Table 2 Therapeutic results in 82 patients
Results No. of patients (%)
Complete response 1 (1%)
Partial response 28 (34%)
Stable disease 36 (44%)
Progressive disease 17 (21%)
Overall response 35% (95% CI: 24–46%).
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lDISCUSSION
Advanced CRC is currently an incurable disease. Therefore, the
objective of treatment must be to prolong survival, obtain effective
control of symptoms and maintain or improve quality of life.
These objectives should be achieved with an acceptable level of
toxicity that does not deteriorate the patient’s quality of life.
At present, many treatments used in advanced CRC are based on
continuous infusion of 5FU modulated by LV, combined with
oxaliplatin or CPT-11. However, continuous infusions require an
indwelling central venous catheter, which is a potential risk for
infection and thrombosis. Moreover, continuous infusions in-
crease treatment costs and probably reduce patient quality of life.
Therefore, the development of schemes with oral fluoropyrimi-
dines that can replace 5FU continuous infusion effectively is an
area of research to pursue given the potential enhanced
convenience and cost benefits. The aims of our study were to
obtain the same therapeutic results as 5FU–LV–oxaliplatin, but
with greater convenience for the patient by avoiding the use of
infusion pumps. The results obtained show that the combination
UFT–l,LV–oxaliplatin is relatively effective in advanced CRC, with
overall response rates of 35% and a median survival rate of 16.8
months. Although the response rate is somewhat lower than the
45–60% response rate reported with other oxaliplatin–5FU–LV
schemes in first-line therapy of advanced CCR (Bertheault-
Cvitkovik et al, 1996; de Gramont et al, 2000; Giacchetti et al,
2000; Goldberg et al, 2003), it does not differ significantly from
those reported in different Phase II studies with oxaliplatin–
capecitabine (31–55%) (Shields et al, 2002; Makatsoris et al, 2003;
Tabernero et al, 2003; Zeuli et al, 2003). On the other hand, time to
progression and median survival rate are similar to those obtained
with these combinations (Bertheault-Cvitkovik et al, 1996; de
Gramont et al, 2000; Giacchetti et al, 2000; Shields et al, 2002;
Louvet and de Gramont, 2003; Makatsoris et al, 2003; Simpson
et al, 2003; Tabernero et al, 2003; Zeuli et al, 2003). Notwithstand-
ing, it can be mentioned that radiological responses were not
reviewed by an IRC, and this could have overestimated our results.
In all events, in the absence of Phase III trials with which we can
compare these schemes directly, we should use these comparisons
with caution.
With regard to toxicity, we should point out the high levels of
gastrointestinal toxicity obtained with the initially planned dose of
UFT 390mgm
2, as 56% of the patients who received this dose
developed some form of grade 3–4 toxicity. After reducing the
UFT dose to 300mgm
2 in the subsequent patients, the incidence
of grade 3–4 diarrhoea fell to 21% of patients and grade 3–4
nausea and vomiting to 14%. These figures are similar to those
reported with 5FU–LV–oxaliplatin schemes (Simpson et al, 2003),
although the latter reported a higher frequency of grade 3–4
neutropenia (41–48% of patients) (de Gramont et al, 2000;
Giacchetti et al, 2000) than that detected in our study (3%).
Relatively few authors have investigated the combination of
oxaliplatin–UFT with or without LV, in comparison to the
association of oxaliplatin–capecitabine. In a Phase II study on
34 patients previously treated with a fluoropyrimidine-based
regimen, oxaliplatin 130mgm
2 was administered every 21 days
with UFT doses of 350mgm
2 for 21 days, without modulation by
LV. The response rate was 13% and grade 3–4 toxicity was
exceptional, with just one episode of Grade 3 neutropenia (Kim
et al, 2002). In another Phase II trial that included 64 patients,
oxaliplatin 130mgm
2 was administered with UFT (300mgm
2)
for 2 weeks, modulated by LV. An overall response rate of 34% and
a median time to progression of 5.9 months were obtained, with
12% of patients developing grade 3–4 neutropenia, 11% grade 3
diarrhoea and 8% suffering from grade 3 nausea/vomiting
(Douillard et al, 2004). These data coincide with what we have
observed in our series.
We could conclude by saying that the results of our study
suggest that UFT/l,LV and oxaliplatin can be combined safely. The
recommended dose for future studies is UFT 300mgm
2, days 1–
14, l,LV 250mgm
2 i.v. on day 1, l,LV 15mgday
1, days 2–14 and
oxaliplatin 85mgm
2 on days 1 and 14, with repeat treatments
every 4 weeks. This is an active scheme with a 35% response rate
and a median survival of 16.5 months. It has acceptable toxicity
and offers the advantage of convenience with its oral administra-
tion. Hence, this regimen is worthy of further investigation.
REFERENCES
Advanced Colorectal Meta-Analysis Project (1992) Modulation of fluor-
ouracil by leucovorin in patients with advanced colorectal cancer:
evidence in terms of response rate. J Clin Oncol 10: 896–903
Bertheault-Cvitkovik F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam
R, Kustlinger F, Bismuth H, Misset JL, Levi F (1996) Biweekly intensified
ambulatory chronomodulated chemotherapy with oxaliplatin, fluoro-
uracil, and leucovorin in patients with metastatic colorectal cancer. J Clin
Oncol 14: 2950–2958
Borner MM, Scho ¨ffski P, de Wit R, Caponigro F, Comella G, Sulkes A,
Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C,
Fumoleau P (2002) Patient preference and pharmacokinetics of oral
modulated UFT versus intravenous fluorouracil and leucovorin: a
Table 3 Toxicity by patients
UFT 390mgm
2, 16 pts. UFT 300mgm
2, 66 pts.
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Nausea/vomiting 12 (75%) 3 (19%) 32 (48%) 9 (14%)
Diarrhoea 4 (25%) 9 (56%) 28 (42%) 14 (21%)
Stomatitis 4 (25%) 0 9 (14%) 1 (1%)
Gastric pain
a 3 (19%) 0 5 (8%) 0
Neutropenia 3 (19%) 1 (6%) 18 (27%) 2 (3%)
Thrombocytopenia 10 (62%) 0 32 (48%) 1 (1%)
Anaemia 9 (56%) 0 32 (48%) 3 (5%)
Asthenia 12 (75%) 4 (25%) 25 (38%) 6 (9%)
Sensitive neuropathy 10 (62%) 3 (18%) 39 (59%) 9 (14%)
Transaminases 6 (37%) 0 22 (33%) 0
aGastric pain: Grade 1–2: abated with antacids or H2-blockers. Grade 3–4: intense enough to require withdrawal of UFT.
UFT and oxaliplatin in the treatment of advanced CRC
J Feliu et al
1761
British Journal of Cancer (2004) 91(10), 1758–1762 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lrandomised crossover trial in advanced colorectal cancer. Eur J Cancer
38: 349–358
Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oca A, Skovsgaard
T, Munier S, Martin C (2002) Randomized coparative study of tegafur/
uracil and oral leucovorin in patients with previously untreated
metastatic colorectal cancer. J Clin Oncol 20: 3617–3627
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni
C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N,
Louvet C, Hendler D, Braud F, Wilson C, Morvan F, Bonetti A (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line
treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
Douillard JY, Bennoua J, Artru P, Perrier H, Paillot B, Hussein F, Priou F,
Imadalou K, Delord JP, Bugat R (2004) UFT/LV combination based
regimens with oxaliplatin or irinotecan as first line treatment for
patients (pts) with non respectable metastatic colorectal cancer (MCRC):
results of two multicentric phase II trials. Proc Am Soc Clin Oncol 23: 256
(abstr. 3545)
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P,
Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P
(2000) Irinotecan combined with fluorouracil compared with fluorour-
acil alone as first-line treatment for metastatic colorectal cancer: a
multicentre randomised trial. Lancet 355: 1041–1047
Douillard J-Y, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P,
Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002)
Multicenter phase III study of uracil/tegafur and oral leucovorin versus
fluorouracil and leucovorin in patients with previously untreated
metastatic colorectal cancer. J Clin Oncol 20: 3605–3616
Eng C, Kindler HL, Schilsky RL (2001) Oral fluoropyrimidine treatment of
colorectal cancer. Clin Colorectal Cancer 1: 95–103
Feliu J, Gonza ´lez Baro ´n M, Espinosa E, Garcı ´a Giro ´nC ,d el aG a ´ndara I,
Espinosa J, Colmenarejo A, Jalo ´n JI, Ferna ´ndez Y, de Castro J (1997)
Uracil and tegafur modulated with leucovorin. An effective regimen with
low toxicity for the treatment of colorectal carcinoma in the elderly.
Cancer 79: 1884–1889
Fleming TR (1982) One-sample multiple testing procedure for phase II
clinical trials. Biometrics 38: 143–151
Fujii S, Kitano S, Irenaka K, Shirasak T (1979) Studies on coadministration
of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives.
Jpn J Cancer Chemother 6: 377–384
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet
P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitovich F, Larregain-
Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levy F (2000) Phase
III multicenter randomised trial of oxaliplatin added to chronomodu-
lated fluorouracil–leucovorin as first-line treatment of metastatic
colorectal cancer. J Clin Oncol 18: 136–147
Goldberg R, Morton R, Sargent D, Fuschs C, Ramanthan RK, Williamson
SK, Findley BP (2003) N9741: oxaliplatin or CPT-11+5-fluorouracil/
leucovorin or oxa+CPT 11 in advanced colorectal cancer. Updated
efficacy and quality of life data from an intergroup study. Proc Am Soc
Clin Oncol 22: 252 (abstr. 1009)
Gonza ´lez Baro ´n M, Feliu J, de la Ga ´ndara I, Espinosa E, Colmenarejo A,
Martı ´nez B, Blanco E, Garcı ´a-Giro ´n C, Jua ´rez F, Garrido P, Ordo ´n ˜ez A,
Zamora P (1995) Efficacy of oral tegafur modulation by uracil (UFT) and
leucovorin in advanced colorectal cancer: a phase II study. Eur J Cancer
31: 2215–2219
Gonza ´lez-Baro ´n M, Feliu J, Ordo ´n ˜ez A, Colmenarejo A, Espinosa E, Zamora
P, de la Ga ´ndara I, Jalo ´n JI. (1993) Phase I study of UFT plus leucovorin
in advanced colorectal cancer: a double modulation proposal. Anticancer
Res 13: 759–762
Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J
(1998) Comparison of 5-fluorouracil pharmacokinetics in patients
receiving continuous 5-fluorouracil infusion and oral uracil plus
N1-(2 ´-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085–2088
Kim K, Nam E, Lee NS, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY,
Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH,
Park K, Kang WK (2002) Oxaliplatin and UFT combination chemother-
apy in patients with metastatic colorectal cancer. Am J Clin Oncol 25:
354–357
Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution
with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl
J Med 345: 145–146
Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral
versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115
Louvet C, Coudray AM, Tournigand C, Prevost T, Raymond E, de Gramobt
A, Chazard M, Gespach C (2000) Synergistic antitumoral activity of
combined UFT, folinic acid and oxaliplatin against human colorectal
HT29 cell xenografts in athymic nude mice. Anticancer Drugs 11:
579–582
Louvet C, de Gramont A (2003) Colorectal cancer: integrating oxaliplatin.
Curr Treat Option Oncol 4: 405–411
Makatsoris T, Papadimitrou C, Karina M, Aravantinos G, Economopoulos
T, Bamias A, Vassilakopoulou M, Xiros N, Kalofonos HP, Fountzilas G
(2003) A phase II study of capecitabine and oxaliplatin as first line
treatment for advanced colorectal carcinoma (CRC). A Hellenic
Cooperative Oncology Group (He COG) study. Proc Am Soc Clin Oncol
22: 360 (abstr. 1447)
Mayer RJ (2001) Oral versus intravenous fluoropyrimidines for advanced
colorectal cancer: by either route, it’s all the same. J Clin Oncol 19:
4093–4096
Meta-Analysis Group in Cancer (1998a) Efficacy of intravenous infusion of
fluorouracil compared with bolus administration in advanced colorectal
cancer. J Clin Oncol 16: 301–308
Meta-Analysis Group in Cancer (1998b) Toxicity of fluorouracil in patients
with advanced colorectal cancer: effect of administration schedule and
prognostic factors. J Clin Oncol 16: 3537–3541
Raymond E, Buguet-Fagot C, Djelloul S, Mester J, Cvitkovic E, allain P,
Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in
combination with 5-fluorouracil and the thymidylate synthase inhibitor
A337 in human colon, breast and ovarian cancer. Anticancer Drugs 8:
876–885
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001)
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin:
summary findings of an independent panel. J Clin Oncol 19: 3801–3807
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun
JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal
cancer. N Engl J Med 343: 905–914
Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2002) A phase II trial of
oxaliplatin and capecitabine in patents with advanced colorectal cancer.
Proc Am Soc Clin Oncol 21: 143 (abstr. 568)
Simpson D, Dunn C, Curren M, Goa KL (2003) Oxaliplatin. A review of its
use in combination therapy for advanced metastatic colorectal cancer.
Drugs 63: 2127–2156
Tabernero J, Butts CA, Cassidy J, Conroy T, de Braud F, Dı ´az-Rubio E, Figer
A, Schoeffski P, Grossmann J, Sobrero A, Twelves C, Van Cutsem E
(2003) Capecitabine and oxaliplatin in combination (Xelox), as first line
therapy for patients (pts) with metastatic colorectal cancer (MCRC):
results of an international phase II trial. Proc Am Soc Clin Oncol 21: 133
(abstr. 531)
World Health Organization 1979 WHO Handbook for Reporting Results of
Cancer Treatment WHO offset publication no. 48. Geneva, Switzerland:
WHO
Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V,
Giannarelli D, Cognetti F (2003) Phase II study of capecitabine and
oxaliplatin as first-line treatment in advanced colorectal cancer. Ann
Oncol 14: 1378–1382
UFT and oxaliplatin in the treatment of advanced CRC
J Feliu et al
1762
British Journal of Cancer (2004) 91(10), 1758–1762 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l